Company Overview and News

4
Philips Evolves as a Healthcare Company, Tariffs a Concern

2018-09-21 zacks
On Sep 21, we issued an updated research report on Koninklijke Philips N.V. (PHG - Free Report) . The company reports operations primarily under three segments - Personal Health businesses (accounted for 41.1% of total sales in 2017), Diagnosis & Treatment businesses (38.8%), and Connected Care & Health Informatics businesses (17.8%). The company also identifies HealthTech Other and Legacy Items. Philips is gradually evolving as a healthcare company, having augmented its presence in the domain, primarily driven by an expanding portfolio.
AT PAYC EOG ATP SRE VSH SPG NTAP PHG APRWF

5
PHG / Koninklijke Philips N.V FORM 6-K (Current Report of Foreign Issuer)

2018-08-29 sec.gov - 4
Form 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PHG

3
DSM, Protecting Life And Our Planet

2018-08-28 seekingalpha
Find a big problem and you are likely to find a big solution within a company worthy of investor consideration.
RDS.B RDS.A PEP KDSKF RYDBF RDSB RDSA RYDAF PHG

21
ViewRay: Buy The Secondary

2018-08-23 seekingalpha - 1
The stock's stability following pricing of the secondary offering, key leadership appointments and institutional clustering are green flags.
JNJ VRAY THOR SPNC PHG

1
Masimo Surges, Be Cautious

2018-08-06 seekingalpha
That said, the valuation currently reflects a rosy outlook for revenue growth beyond the next three years.
MASI PHG

3
Koninklijke Philips' (PHG) Q2 Earnings Up Y/Y, Sales Flat

2018-07-25 zacks
Koninklijke Philips N.V. (PHG - Free Report) reported second-quarter 2018 adjusted earnings of €0.30 (24 cents per share), up 50% from the year-ago quarter. Sales were €4.29 billion ($5.11 billion) flat on a year-over-year basis. Comparable sales (includes adjustments for consolidation charges & currency effects) grew 4%, reflecting high-single-digit growth in the Diagnosis & Treatment businesses. Growth in both Connected Care & Health Informatics and Personal Health businesses was at a low-single-digit rate.
DB GRMN MS PHG CIT

1
PHG / Koninklijke Philips N.V FORM 6-K (Current Report of Foreign Issuer)

2018-07-23 sec.gov
Form 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PHG

1
Koninklijke Philips NV's (PHG) CEO Frans van Houten on Q2 2018 Results - Earnings Call Transcript

2018-07-23 seekingalpha
Koninklijke Philips NV (NYSE:PHG) Q2 2018 Results Earnings Conference Call July 23, 2018 5:00 AM ET
DB PHG

11
Amazon Prime Day: 3 Winners, 1 Loser

2018-07-18 investorplace
A few years ago, Prime Day wasn’t even a thing. Now, it is one of the biggest shopping events in the world! It’s such a large shopping event, and it has grown so quickly, that Prime Day has some significant investment implications.
NWL PHG

5
PHG / Koninklijke Philips N.V FORM 6-K (Current Report of Foreign Issuer)

2018-06-06 sec.gov - 1
Form 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PHG

4
PHG / Koninklijke Philips N.V FORM 6-K (Current Report of Foreign Issuer)

2018-06-06 sec.gov
Form 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PHG

4
PHG / Koninklijke Philips N.V null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected](# @;V)J#3P\+TQI;F5A8F)D [email protected]":!"08*T%$"[email protected]@D2JP 1\B""&23V%40L W&[02R08J8L(/%L)P,3 M(\-#(([email protected]$8XC]CVP^ , ?GP+#@T*96YD
PHG

4
PHG / Koninklijke Philips N.V null

2018-05-31 sec.gov
CORRESP A LIMITED LIABILITY PARTNERSHIP
PHG

6
PHG / Koninklijke Philips N.V SD

2018-05-27 sec.gov - 2
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PHG

4
PHG / Koninklijke Philips N.V null

2018-04-28 sec.gov
CORRESP FOIA CONFIDENTIAL TREATMENT REQUEST BY HAND AND VIA EDGAR Cecilia D. Blye Chief
PHG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PHG / Koninklijke Philips N.V on message board site Silicon Investor.

PHGI -Perihelion Global, Inc. PHGI -Perihelion Global, Inc. PHGI -Perihelion Global, Inc. Philips (PHG) Philips (PHG) Philips (PHG)
CUSIP: 500472303